Catridecacog
NovoThirteen (catridecacog) is a protein pharmaceutical. Catridecacog was first approved as NovoThirteen on 2012-09-03. It has been approved in Europe to treat inherited blood coagulation disorders.
| Trade Name | NovoThirteen |
|---|---|
| Common Name | Catridecacog |
| Indication | inherited blood coagulation disorders |
| Drug Class |
